Table 1 Prediction using the 5hmC diagnostic model in AML patients.

From: Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia

 

AML validation set

Non-HSCT

HSCT non-CR

HSCT CR

Control validation set

Wd-score high

23

21

13

7

0

Wd-score low

2

3

2

14

17

Total

25

24

15

21

17

Sensitivity

92.0%

87.5%

87.7%

33.3%

–

Specificity

–

–

–

–

100%

  1. Non-HSCT did not receive hematopoietic stem cell transplantation, HSCT Non-CR received hematopoietic stem cell transplantation and not in complete remission, HSCT CR received hematopoietic stem cell transplantation and in complete remission.
Back to article page